Prio Wealth Limited Partnership Sells 1,500 Shares of Novo Nordisk A/S (NVO)

Prio Wealth Limited Partnership decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 3.1% in the 4th quarter, Holdings Channel reports. The firm owned 47,350 shares of the company’s stock after selling 1,500 shares during the period. Prio Wealth Limited Partnership’s holdings in Novo Nordisk A/S were worth $2,181,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in NVO. Alliancebernstein L.P. acquired a new position in Novo Nordisk A/S during the third quarter worth $70,602,000. Renaissance Technologies LLC lifted its stake in Novo Nordisk A/S by 2.7% in the third quarter. Renaissance Technologies LLC now owns 19,666,671 shares of the company’s stock valued at $927,087,000 after acquiring an additional 524,371 shares during the last quarter. Loomis Sayles & Co. L P lifted its stake in Novo Nordisk A/S by 2.1% in the third quarter. Loomis Sayles & Co. L P now owns 21,742,529 shares of the company’s stock valued at $1,024,943,000 after acquiring an additional 457,466 shares during the last quarter. Fisher Asset Management LLC lifted its stake in Novo Nordisk A/S by 2.9% in the fourth quarter. Fisher Asset Management LLC now owns 14,202,935 shares of the company’s stock valued at $654,329,000 after acquiring an additional 405,531 shares during the last quarter. Finally, Capital International Investors lifted its stake in Novo Nordisk A/S by 80.5% in the third quarter. Capital International Investors now owns 814,915 shares of the company’s stock valued at $38,415,000 after acquiring an additional 363,500 shares during the last quarter. Institutional investors and hedge funds own 6.85% of the company’s stock.

NYSE:NVO traded down $0.20 during mid-day trading on Wednesday, hitting $49.20. 11,986 shares of the company’s stock were exchanged, compared to its average volume of 1,507,950. Novo Nordisk A/S has a fifty-two week low of $41.23 and a fifty-two week high of $54.56. The company has a market cap of $118.95 billion, a PE ratio of 19.54, a P/E/G ratio of 2.30 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Friday, February 1st. The company reported $0.54 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.03). Novo Nordisk A/S had a return on equity of 80.45% and a net margin of 34.67%. The business had revenue of $4.55 billion for the quarter, compared to analyst estimates of $4.36 billion. On average, equities analysts predict that Novo Nordisk A/S will post 2.58 earnings per share for the current fiscal year.

A number of brokerages have commented on NVO. Barclays reiterated a “sell” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 5th. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating and set a $56.00 price target for the company in a research note on Tuesday, February 5th. Handelsbanken cut shares of Novo Nordisk A/S from a “buy” rating to an “accumulate” rating and set a $48.61 price target for the company. in a research note on Monday, February 4th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Friday, February 1st. They set an “equal weight” rating on the stock. Finally, BNP Paribas started coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 29th. They set an “outperform” rating on the stock. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $52.31.

TRADEMARK VIOLATION NOTICE: This article was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.com-unik.info/2019/02/13/prio-wealth-limited-partnership-sells-1500-shares-of-novo-nordisk-a-s-nvo.html.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.

See Also: Strangles

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit